Navigation Links
Potential treatment for deadly E. coli disease
Date:6/7/2011

A potential life-saving treatment for severe E. coli food poisoning outbreaks developed more than a decade ago hasn't gone forward into clinical trials because of lack of commercial interest.

University of Adelaide researchers produced a "designer" probiotic bacterium which binds and neutralises the toxin produced by E. coli, which causes life-threatening attack on the kidneys and blood vessels.

The team of scientists Dr Adrienne Paton, Associate Professor Renato Morona and Professor James Paton showed that mice infected with a highly virulent strain of E. coli were completely protected by the probiotic bacterium.

The research was published in the prestigious journal Nature Medicine in 2000 and generated ongoing interest from the scientific and medical community but the commercial sector hasn't taken up its development for progress into clinical trials in humans.

"Severe E. coli food poisoning outbreaks such as that currently occurring in Europe are becoming increasingly common," said Professor Paton, Director, Research Centre for Infectious Diseases at the University of Adelaide.

"They have the potential to cause widespread disease and many patients develop life-threatening complications including kidney failure.

"The probiotic bacterium could be produced cheaply on a large scale. However, in spite of on-going attention from the scientific and medical community, there has been a lack of interest from the commercial sector in taking this product forward into clinical trials.

"If this had been done, and the probiotic had been proven to be safe and efficacious in humans, it could have been deployed during the current European outbreak. This would undoubtedly have saved lives, as well as millions of dollars in current and future health care costs."

The researchers engineered a harmless bacterium to mimic binding receptors for the potentially fatal Shiga toxin on its surface.

Professor Paton said after diagnosis of E. coli infection there was a window of opportunity for therapeutic intervention before kidneys started to fail. Antibiotics are not used because they can increase the amount of toxin released in the gut.


'/>"/>

Contact: Professor James Paton
james.paton@adelaide.edu.au
61-414-732-967
University of Adelaide
Source:Eurekalert

Related biology news :

1. Estimating landfill gas potential
2. CDC assesses potential human exposure to prion diseases
3. Scientists find new class of compounds with great potential for research and drug development
4. Liquid smoke from rice shows potential health benefits
5. CHOP partners with Vascular Magnetics, Inc. to pursue commercial potential of blood vessel research
6. Discovery demonstrates potential MS therapy could kill brain cells
7. GW researchers reveal 18 novel subtype-dependent genetic variants for autism spectrum disorders and identify potential genetic markers for diagnostic screening
8. Satellite tracking of sea turtles reveals potential threat posed by manmade chemicals
9. Viral replicase points to potential cancer therapy
10. School energy audits find millions in potential energy savings
11. A diabetes drug, sitagliptin, also has a potential to prevent diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s Medical ... place on 7th and 8th June 2018 in San Francisco, CA. The Summit brings ... well as several distinguished CEOs, board directors and government officials from around the world ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
Breaking Biology Technology: